Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Blinatumomab vs inotuzumab ozogamicin for ALL

Talha Badar • 2 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a multi-cohort analysis which aimed to evaluate the efficacy of blinatumomab versus inotuzumab-ozogamicin for B-cell acute lymphoblastic leukemia (ALL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Talha Badar

2:12
The impact of immuno-oncology on ALL outcomes
Talha Badar • 2 Jun 2020
3:17
Trends in post-relapse survival in Hodgkin lymphoma
Talha Badar • 3 Jun 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals